Patents by Inventor Paul Olson
Paul Olson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8865164Abstract: Methods of detecting complement activation including steps of detecting in a sample from a subject a level of iC3b wherein the detecting involves specific interaction between the iC3b and a non-cross-reactive antibody thereto, comparing the detected level with a reference level, which reference level is within a range of about 10 ng/ml to about 5,000 ng/ml, wherein determination that the detected level is above the reference level indicates that the subject is suffering from or susceptible to undesirable and/or pathologic complement activation, and administering treatment to treat undesired complement activation if the detected level is above the reference level. Other methods of detecting complement activation with or without measuring iC3b are also provided.Type: GrantFiled: May 1, 2012Date of Patent: October 21, 2014Assignee: Kypha, Inc.Inventors: Paul Olson, Don W. Moss, Nicholas Staten
-
Publication number: 20140050739Abstract: The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.Type: ApplicationFiled: October 11, 2013Publication date: February 20, 2014Applicant: Apellis Pharmaceuticals, Inc.Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
-
Patent number: 8580735Abstract: The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.Type: GrantFiled: February 5, 2008Date of Patent: November 12, 2013Assignee: Apellis Pharmaceuticals, Inc.Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
-
Publication number: 20130296254Abstract: The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.Type: ApplicationFiled: March 1, 2012Publication date: November 7, 2013Applicant: POTENTIA PHARMACEUTICALS, INC.Inventors: Pascal Deschatelets, Paul Olson, Cedric Francois
-
Publication number: 20130072442Abstract: The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.Type: ApplicationFiled: October 3, 2011Publication date: March 21, 2013Applicant: POTENTIA PHARMACEUTICALS, INC.Inventors: Pascal Deschatelets, Paul Olson, Cedric Francois
-
Publication number: 20120315266Abstract: Methods of detecting complement activation including steps of detecting in a sample from a subject a level of iC3b wherein the detecting involves specific interaction between the iC3b and a non-cross-reactive antibody thereto, comparing the detected level with a reference level, which reference level is within a range of about 10 ng/ml to about 5,000 ng/ml, wherein determination that the detected level is above the reference level indicates that the subject is suffering from or susceptible to undesirable and/or pathologic complement activation, and administering treatment to treat undesired complement activation if the detected level is above the reference level. Other methods of detecting complement activation with or without measuring iC3b are also provided.Type: ApplicationFiled: May 1, 2012Publication date: December 13, 2012Applicant: KYPHA, INC.Inventors: Paul Olson, Don W. Moss, Nicholas Staten
-
Publication number: 20120225114Abstract: The present invention provides compositions and methods for modulating one or more phenotypes of a macrophage-related cell, e.g., a macrophage. The invention further provides methods of treating disease by modulating macrophage phenotype. Representative phenotypes include pro-inflammatory, anti-inflammatory, immunogenic, tolerogenic, tissue-destructive, tissue restorative, cytotoxic, migratory, bone-resorbing, pro-angiogenic, anti-angiogenic, suppressor, antigen presentation, or phagocytic. Representative diseases include atherosclerosis, arthritis, and multiple sclerosis.Type: ApplicationFiled: December 1, 2011Publication date: September 6, 2012Applicant: APELLIS PHARMACEUTICALS, INC.Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
-
Patent number: 8198020Abstract: The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular molecular entities by tagging such cells or noncellular molecular entities with a marker that targets the cells or noncellular molecular entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagcytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.Type: GrantFiled: August 23, 2004Date of Patent: June 12, 2012Assignee: Potentia Pharmaceuticals, Inc.Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson, Alec Machiels
-
Publication number: 20120141457Abstract: A method for treating an individual at risk for a complement-associated disorder is provided, including: (a) obtaining a sample of a body fluid from the individual; (b) measuring a complement activation level in the sample via a point-of-care lateral flow immunoassay; (c) correlating the complement activation level in the sample to a risk of a complement-associated disorder by comparing the complement activation level in the sample to a reference level in a control, wherein a deviation in complement activation level in the sample compared to the reference level in the control indicates the individual is at risk for a complement-associated disorder; (d) selecting a treatment for the individual, based on the correlating of step (c); and (e) treating the individual with the treatment selected in accordance with step (d). Lateral flow immunoassays and a method of monitoring an individual suffering from a complement-associated disorder are also provided herein.Type: ApplicationFiled: November 2, 2011Publication date: June 7, 2012Applicant: Kypha, Inc.Inventors: Paul Olson, Don W. Moss
-
Publication number: 20120135430Abstract: The present invention provides methods for assessing complement activation and methods for assessing the ability of an agent or condition of interest to modulate complement activation. The present invention provides methods for assessing whether a subject has or is at increased risk of developing a complement-mediated disorder, e.g., age-related macular degeneration (AMD). Also provided are kits containing materials useful for performing the methods.Type: ApplicationFiled: May 21, 2010Publication date: May 31, 2012Applicant: POTENTIA PHARMACEUTICALS, INC.Inventors: Zhouning Zhang, Cedric Francois, Pascal Deschatelets, Paul Olson
-
Patent number: 8168584Abstract: The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.Type: GrantFiled: October 6, 2006Date of Patent: May 1, 2012Assignee: Potentia Pharmaceuticals, Inc.Inventors: Pascal Deschatelets, Paul Olson, Cedric Francois
-
Patent number: 8043609Abstract: The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.Type: GrantFiled: December 19, 2006Date of Patent: October 25, 2011Assignee: Potentia Pharmaceuticals, Inc.Inventors: Pascal Deschatelets, Paul Olson, Cedric Francois
-
Publication number: 20110190221Abstract: The present invention features the use of selected complement activation inhibitor(s) for treating an individual who has suffered a severe injury. The complement activation inhibitor acts at or above the level of C3 activation and does not significantly deplete or irreversibly inhibit complement activation. Also provided are compositions and methods for repleting and/or enhancing complement activation capacity in a subject who has suffered a traumatic injury.Type: ApplicationFiled: March 30, 2009Publication date: August 4, 2011Applicant: APELLIS AGInventors: Cedric Francois, Pascal Deschatelets, Paul Olson
-
Publication number: 20110182877Abstract: The present invention features the sustained delivery of compstatin analog and, optionally, an additional active agent, by release from a macroscopic, gel-like deposit formed by administering a liquid solution containing the compstatin analog to an extravascular location in the body of a mammalian subject such as the vitreous chamber.Type: ApplicationFiled: October 2, 2008Publication date: July 28, 2011Applicant: POTENTIA PHARMACEUTICALS, INC.Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
-
Patent number: 7947267Abstract: The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.Type: GrantFiled: October 8, 2005Date of Patent: May 24, 2011Assignee: Potentia Pharmaceuticals, Inc.Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
-
Publication number: 20110092446Abstract: The present invention features the use of a complement inhibitor, e.g., a compstatin analog for treating an individual who has suffered a severe injury. In some embodiments, the complement inhibitor may be administered within 24 hours following the injury and optionally also at later time points. The complement inhibitor may, for example, be administered prior to transporting the patient to a health care facility, during transport of the patient to a health care facility, or in the emergency department. Further provided are methods of selecting individuals for such therapy. Further provided are methods of identifying individuals at increased risk of poor outcome following trauma. In certain embodiments the methods comprise determining whether the genotype of the patient includes an allele of a polymorphism in or near a complement-related gene, wherein said allele is associated with risk of poor outcome following trauma.Type: ApplicationFiled: July 21, 2008Publication date: April 21, 2011Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
-
Publication number: 20100166862Abstract: The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.Type: ApplicationFiled: February 5, 2008Publication date: July 1, 2010Applicant: POTENTIA PHARMACEUTICALS, INC.Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
-
Publication number: 20090220572Abstract: The present invention provides composition, methods, and articles of manufacture for treating an eye disorder, e.g., a disorder characterized by macular degeneration, choroidal neovascularization, or retinal neovascularization. One method of the invention comprises the step of: administering first and second therapeutic agents to the subject's eye in a single procedure, wherein the first therapeutic agent provides rapid improvement in the condition of the subject's eye and the second therapeutic agent is administered as a sustained release formulation of the second therapeutic agent. For example, the first and second therapeutic agents are administered by intravitreal injection. The first therapeutic agent may be dissolved in a liquid medium located in the syringe and the sustained formulation of the second therapeutic agent may comprise an ocular implant or plurality of particles located in the needle.Type: ApplicationFiled: January 19, 2007Publication date: September 3, 2009Applicant: POTENTIA PHARMACEUTICALS, INC.Inventors: Pascal Deschatelets, Paul Olson, Cedric Francois
-
Publication number: 20090117171Abstract: The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. The methods comprise administering a composition comprising a compound that is an antagonist of a G protein coupled receptor, e.g., the C5a receptor, to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization. The invention provides compositions comprising a compound that is an antagonist of a G protein coupled receptor linked either directly or indirectly to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization.Type: ApplicationFiled: March 13, 2006Publication date: May 7, 2009Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
-
Patent number: D591444Type: GrantFiled: December 3, 2008Date of Patent: April 28, 2009Assignee: Oldenburg Group IncorporatedInventors: Jimalee R. Beno, Michael A. Arndt, Paul A. Olson